DK1071449T3 - Anvendelse af et antagonistantistof mod den inflammatoriske mediator Oncostatin M (OSM) - Google Patents
Anvendelse af et antagonistantistof mod den inflammatoriske mediator Oncostatin M (OSM)Info
- Publication number
- DK1071449T3 DK1071449T3 DK99911954T DK99911954T DK1071449T3 DK 1071449 T3 DK1071449 T3 DK 1071449T3 DK 99911954 T DK99911954 T DK 99911954T DK 99911954 T DK99911954 T DK 99911954T DK 1071449 T3 DK1071449 T3 DK 1071449T3
- Authority
- DK
- Denmark
- Prior art keywords
- osm
- oncostatin
- antibody against
- antagonist antibody
- inflammatory mediator
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806530.3A GB9806530D0 (en) | 1998-03-26 | 1998-03-26 | Inflammatory mediator |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1071449T3 true DK1071449T3 (da) | 2007-01-02 |
Family
ID=10829337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99911954T DK1071449T3 (da) | 1998-03-26 | 1999-03-25 | Anvendelse af et antagonistantistof mod den inflammatoriske mediator Oncostatin M (OSM) |
Country Status (20)
Country | Link |
---|---|
US (5) | US6706266B1 (da) |
EP (2) | EP1849478A3 (da) |
JP (2) | JP3825255B2 (da) |
KR (1) | KR20010034672A (da) |
CN (1) | CN1295482A (da) |
AT (1) | ATE338565T1 (da) |
AU (1) | AU3046399A (da) |
BR (1) | BR9909077A (da) |
CA (1) | CA2325585A1 (da) |
CY (1) | CY1105722T1 (da) |
DE (1) | DE69933115T2 (da) |
DK (1) | DK1071449T3 (da) |
ES (1) | ES2272058T3 (da) |
GB (1) | GB9806530D0 (da) |
HU (1) | HUP0101690A2 (da) |
IL (1) | IL138604A0 (da) |
PL (1) | PL343431A1 (da) |
PT (1) | PT1071449E (da) |
WO (1) | WO1999048523A2 (da) |
ZA (1) | ZA200005076B (da) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
WO2001081345A1 (fr) * | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Composes d'amides aromatiques |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
WO2003035048A2 (en) * | 2001-10-26 | 2003-05-01 | Novartis Ag | Methods for the treatment of osteoarthritis and compositions thereof |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
EP1581169A4 (en) * | 2002-11-08 | 2008-09-17 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS |
JP4803789B2 (ja) * | 2004-02-03 | 2011-10-26 | 独立行政法人科学技術振興機構 | 疼痛を処置するための薬学的組成物 |
CA2562953A1 (en) * | 2004-03-30 | 2005-10-13 | Glaxo Group Limited | Humanized and chimeric anti-osm antibodies |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
EP1795204A4 (en) * | 2004-09-29 | 2009-10-21 | Asama Kasei Kk | FUNCTIONAL COMPOSITION OR FOODS WITH MOLKEPROTEIN, FROM MILK-ORGANIC ANTIBODIES OR ANTIBODIES |
US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
EP1671642A1 (en) * | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
US20060276440A1 (en) * | 2005-01-03 | 2006-12-07 | An Wenqian F | Treatment of inflammatory disorders |
EP1877556B1 (en) * | 2005-03-25 | 2011-09-14 | Medtronic, Inc. | Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain |
EP1915436B1 (en) * | 2005-08-02 | 2011-09-28 | Trustees Of Tufts College | Methods for stepwise deposition of silk fibroin coatings |
WO2008134077A1 (en) * | 2007-04-30 | 2008-11-06 | Archemix Corp. | Metabolic profile directed aptamer medicinal chemistry |
JP2010532790A (ja) * | 2007-07-06 | 2010-10-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗体処方 |
US8030290B2 (en) | 2007-12-07 | 2011-10-04 | City Of Hope | Cell-type specific aptamer-siRNA delivery system for HIV-1 Therapy |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
US8309688B2 (en) * | 2008-12-30 | 2012-11-13 | Centocor Ortho Biotech Inc. | Monkey homolog of human oncostatin M and methods of use thereof |
EP2401297A1 (en) * | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
WO2011080050A2 (en) | 2009-12-11 | 2011-07-07 | Novartis Ag | Binding molecules |
WO2011094259A2 (en) | 2010-01-28 | 2011-08-04 | Glaxo Group Limited | Cd127 binding proteins |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
ES2717908T3 (es) | 2010-06-14 | 2019-06-26 | Lykera Biomed S A | Anticuerpos S100A4 y usos terapéuticos de los mismos |
EA031044B1 (ru) * | 2010-10-13 | 2018-11-30 | Янссен Байотек, Инк. | Человеческие антитела к онкостатину м и способы их применения |
KR20210021109A (ko) | 2010-11-08 | 2021-02-24 | 제넨테크, 인크. | 피하 투여용 항―il―6 수용체 항체 |
WO2012069433A2 (en) * | 2010-11-23 | 2012-05-31 | Glaxo Group Limited | Antigen binding proteins |
WO2013168829A1 (en) | 2012-05-11 | 2013-11-14 | Wakayama Medical University | Anti oncostatin m receptor beta antibody |
US9663571B2 (en) | 2013-05-30 | 2017-05-30 | Kiniksa Pharmaceuticals, Ltd. | Oncostatin M receptor antigen binding proteins |
US10307487B2 (en) * | 2013-07-09 | 2019-06-04 | President And Fellows Of Harvard College | Microvessel endothelial cell surface markers and uses thereof |
US9550828B2 (en) * | 2013-09-05 | 2017-01-24 | Boise State University | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders |
JP2014062100A (ja) * | 2013-11-05 | 2014-04-10 | Glaxosmithkline Llc | 抗体処方 |
EP3069137A1 (en) | 2013-11-05 | 2016-09-21 | Novartis Ag | Organic compounds |
CN104096219A (zh) * | 2014-07-08 | 2014-10-15 | 武汉大学 | Ⅱ型抑瘤素m受体(osmr)在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 |
EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
WO2016046738A1 (en) | 2014-09-24 | 2016-03-31 | Università Degli Studi Di Padova | Composition to induce bone marrow stem cell mobilization |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
WO2016120625A1 (en) * | 2015-01-29 | 2016-08-04 | Isis Innovation Limited | Biomarker |
GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
US11633457B2 (en) | 2019-04-11 | 2023-04-25 | Boise State University | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US646727A (en) * | 1899-06-20 | 1900-04-03 | Columbia Motor And Mfg Company | Steam-generator. |
US5618715A (en) * | 1985-12-20 | 1997-04-08 | Oncogen Limited Partnership | Oncostatin M and novel compositions having anti-neoplastic activity |
US5681930A (en) * | 1985-12-20 | 1997-10-28 | Bristol-Myers Squibb Company | Anti-oncostatin M monoclonal antibodies |
JPS6463395A (en) | 1987-05-04 | 1989-03-09 | Oncogen | Oncostatin m and novel composition having antitumor activity |
US5814307A (en) | 1989-04-10 | 1998-09-29 | Bristol-Myers Squibb Company | Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6 |
DK0422186T3 (da) | 1989-04-10 | 1999-08-16 | Oncogen | Anvendelse af oncostatin M til suppression af MHC-antigener |
AU651330B2 (en) | 1989-12-08 | 1994-07-21 | Oncogen Limited Partnership | Novel proteins with oncostatin M activity and process for their preparation |
NZ237533A (en) * | 1990-03-29 | 1992-12-23 | Bristol Myers Squibb Co | Monoclonal antibodies which bind to oncostatin m, cell lines producing them |
DE4011684A1 (de) | 1990-04-06 | 1991-10-10 | Schering Ag | Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung |
CA2055122A1 (en) | 1990-11-13 | 1992-05-14 | Robert I. Grove | Methods for stimulating ldl uptake and ldl receptor expression |
AU666866B2 (en) | 1991-08-30 | 1996-02-29 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US6171824B1 (en) | 1991-08-30 | 2001-01-09 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US5262522A (en) * | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH05304986A (ja) | 1992-04-28 | 1993-11-19 | Tosoh Corp | gp130蛋白質に対するモノクロ−ナル抗体 |
US5744442A (en) | 1992-08-26 | 1998-04-28 | Bristol Meyers Squibb Company | Regulation of cellular invasiveness |
US5460810A (en) | 1992-09-02 | 1995-10-24 | Genetics Institute, Inc. | Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11 |
IT1261787B (it) | 1993-06-23 | 1996-06-03 | Angeletti P Ist Richerche Bio | Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. |
FR2707882B1 (fr) * | 1993-07-23 | 1997-08-01 | Immunotech Sa | Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant. |
US5451411A (en) * | 1993-10-15 | 1995-09-19 | University Of Washington | Methods and compositions for the oral delivery of therapeutic agents |
US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
GB9419021D0 (en) | 1994-09-21 | 1994-11-09 | Applied Research Systems | Therapeutic protein |
US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
JPH09117288A (ja) | 1995-06-06 | 1997-05-06 | Bristol Myers Squibb Co | オンコスタチンm誘導造血 |
WO1997016202A1 (en) | 1995-10-27 | 1997-05-09 | Amrad Operations Pty. Ltd. | Cytokines and their use in treatment and/or prophylaxis of breast cancer |
WO1998018483A1 (en) | 1996-10-25 | 1998-05-07 | Bristol-Myers Squibb Company | Oncostatin m for treating inflammation |
US5958442A (en) * | 1997-10-24 | 1999-09-28 | Bristol-Myers Squibb Company | Oncostatin M for treating inflammation |
GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
-
1998
- 1998-03-26 GB GBGB9806530.3A patent/GB9806530D0/en not_active Ceased
-
1999
- 1999-03-25 EP EP06119544.2A patent/EP1849478A3/en not_active Withdrawn
- 1999-03-25 DK DK99911954T patent/DK1071449T3/da active
- 1999-03-25 DE DE69933115T patent/DE69933115T2/de not_active Expired - Lifetime
- 1999-03-25 HU HU0101690A patent/HUP0101690A2/hu unknown
- 1999-03-25 KR KR1020007010639A patent/KR20010034672A/ko not_active Application Discontinuation
- 1999-03-25 AU AU30463/99A patent/AU3046399A/en not_active Abandoned
- 1999-03-25 WO PCT/GB1999/000943 patent/WO1999048523A2/en active IP Right Grant
- 1999-03-25 AT AT99911954T patent/ATE338565T1/de active
- 1999-03-25 CA CA002325585A patent/CA2325585A1/en not_active Abandoned
- 1999-03-25 CN CN99804497A patent/CN1295482A/zh active Pending
- 1999-03-25 EP EP99911954A patent/EP1071449B1/en not_active Expired - Lifetime
- 1999-03-25 BR BR9909077-5A patent/BR9909077A/pt not_active Application Discontinuation
- 1999-03-25 ES ES99911954T patent/ES2272058T3/es not_active Expired - Lifetime
- 1999-03-25 PL PL99343431A patent/PL343431A1/xx not_active Application Discontinuation
- 1999-03-25 US US09/276,147 patent/US6706266B1/en not_active Expired - Lifetime
- 1999-03-25 JP JP2000537570A patent/JP3825255B2/ja not_active Expired - Lifetime
- 1999-03-25 IL IL13860499A patent/IL138604A0/xx unknown
- 1999-03-25 PT PT99911954T patent/PT1071449E/pt unknown
-
2000
- 2000-09-21 ZA ZA200005076A patent/ZA200005076B/en unknown
-
2003
- 2003-05-21 US US10/442,289 patent/US20040081650A1/en not_active Abandoned
-
2005
- 2005-10-27 US US11/260,844 patent/US7291332B2/en not_active Expired - Fee Related
-
2006
- 2006-05-08 JP JP2006129454A patent/JP2006290893A/ja not_active Withdrawn
- 2006-10-24 CY CY20061101520T patent/CY1105722T1/el unknown
-
2007
- 2007-05-09 US US11/746,090 patent/US8003101B2/en not_active Expired - Fee Related
- 2007-09-20 US US11/858,308 patent/US20080019967A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PT1071449E (pt) | 2006-12-29 |
US8003101B2 (en) | 2011-08-23 |
IL138604A0 (en) | 2001-10-31 |
JP3825255B2 (ja) | 2006-09-27 |
US20040081650A1 (en) | 2004-04-29 |
ZA200005076B (en) | 2001-09-21 |
JP2006290893A (ja) | 2006-10-26 |
BR9909077A (pt) | 2000-12-05 |
JP2002507580A (ja) | 2002-03-12 |
WO1999048523A2 (en) | 1999-09-30 |
US20080044409A1 (en) | 2008-02-21 |
US20060093602A1 (en) | 2006-05-04 |
KR20010034672A (ko) | 2001-04-25 |
EP1849478A3 (en) | 2013-05-29 |
GB9806530D0 (en) | 1998-05-27 |
WO1999048523A3 (en) | 1999-11-25 |
DE69933115D1 (de) | 2006-10-19 |
CA2325585A1 (en) | 1999-09-30 |
EP1071449B1 (en) | 2006-09-06 |
AU3046399A (en) | 1999-10-18 |
CY1105722T1 (el) | 2010-12-22 |
US7291332B2 (en) | 2007-11-06 |
PL343431A1 (en) | 2001-08-13 |
ATE338565T1 (de) | 2006-09-15 |
EP1071449A2 (en) | 2001-01-31 |
US20080019967A1 (en) | 2008-01-24 |
CN1295482A (zh) | 2001-05-16 |
DE69933115T2 (de) | 2007-04-05 |
EP1849478A2 (en) | 2007-10-31 |
HUP0101690A2 (hu) | 2001-08-28 |
ES2272058T3 (es) | 2007-04-16 |
US6706266B1 (en) | 2004-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1071449T3 (da) | Anvendelse af et antagonistantistof mod den inflammatoriske mediator Oncostatin M (OSM) | |
EA200301073A1 (ru) | N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора | |
CY1105386T1 (el) | Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου | |
EA200300580A1 (ru) | Соединения лактама | |
EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
DK1017713T3 (da) | Cykliske antagonister af C5a-receptorer og G-protein-koblede receptorer | |
DK2314319T3 (da) | Sammensætninger til rensning af colon | |
CY1106247T1 (el) | Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες | |
EA200101177A1 (ru) | Производные индола в качестве антагонистов прогестерона | |
EA200601553A1 (ru) | Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды | |
DK1337518T3 (da) | Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren | |
EA200100411A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
EA200100412A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
EA200100773A1 (ru) | Замещенные 1-гетероциклические диариламины | |
DK1355644T3 (da) | Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi | |
EA200301100A1 (ru) | Новые фталазиноны | |
EA200300829A1 (ru) | Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6 | |
EA200300593A1 (ru) | Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора | |
EA200001039A1 (ru) | Кальцилитические соединения | |
EA200200732A1 (ru) | Замещенные производные фенилпиперазина, их получение и применение | |
EA200400454A1 (ru) | Мускариновые агонисты | |
EA200501341A1 (ru) | Противобактериальные индолоноксазолидиноны, промежуточные соединения для их получения и содержащие их фармацевтические композиции | |
EA200300988A1 (ru) | Производные фенил-гетероциклильных эфиров в качестве ингибиторов обратного захвата серотонина | |
DE60202669D1 (de) | 6-phenylbenzonaphthyidine | |
ATE441642T1 (de) | Hydantoin derivate mit affinität für somatostatin rezeptoren |